The Present and Future of THERANOSTICS.

IF 2.1 4区医学 Q4 ONCOLOGY

Asia-Pacific journal of clinical oncology Pub Date : 2026-06-02 DOI:10.1111/ajco.70126

Winnie Wing-Chuen Lam, Sue Ping Thang, Kelvin Siu-Hoong Loke, Pei Ing Ngam, Andrew Eik-Hock Tan, Lenith Tai-Jit Cheng, Sidney Yu, Anna Ler, Damian Li-Kin Khor, Soma Somanesan, David Chee Eng Ng

引用次数: 0

Abstract

There is a growing worldwide interest in the detection and targeted treatment of cancer with radiotheranostics as part of precision medicine. This article reviews some of the developments in theranostics, namely, approved radiopharmaceuticals, agents in late-stage clinical trials, emerging radionuclides and targets, as well as operational and regulatory challenges. Other areas of development include use of novel ligands, new indications, and combinations with other systemic therapies. We aim to provide an overview of radiopharmaceutical therapies in use and in clinical development and consider some of the challenges in East and Southeast Asia, including an innovative yet highly regulated environment in Singapore.

查看原文本刊更多论文

治疗学的现在和未来。

作为精密医学的一部分，世界范围内对放射治疗癌症的检测和靶向治疗越来越感兴趣。本文回顾了治疗学的一些发展，即批准的放射性药物，后期临床试验中的药物，新出现的放射性核素和靶标，以及操作和监管方面的挑战。其他发展领域包括使用新的配体、新的适应症和与其他全身疗法的联合。我们的目标是概述使用和临床开发中的放射性药物治疗，并考虑东亚和东南亚的一些挑战，包括新加坡创新但高度监管的环境。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Asia-Pacific journal of clinical oncology 医学-肿瘤学

CiteScore

3.40

自引率

0.00%

发文量

175

审稿时长

6-12 weeks

期刊介绍： Asia–Pacific Journal of Clinical Oncology is a multidisciplinary journal of oncology that aims to be a forum for facilitating collaboration and exchanging information on what is happening in different countries of the Asia–Pacific region in relation to cancer treatment and care. The Journal is ideally positioned to receive publications that deal with diversity in cancer behavior, management and outcome related to ethnic, cultural, economic and other differences between populations. In addition to original articles, the Journal publishes reviews, editorials, letters to the Editor and short communications. Case reports are generally not considered for publication, only exceptional papers in which Editors find extraordinary oncological value may be considered for review. The Journal encourages clinical studies, particularly prospectively designed clinical trials.